Ionis Pharma

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ionis Pharma excels in Q4, eyes revenue growth and strategic expansion

Ionis Pharma's Q4 2022 performance reflects strong revenue growth, pipeline advancements, and strategic positioning for future success.
The company's focus on commercialization, R&D innovation, and financial discipline underscores its resilience and growth potential in the biopharmaceutical industry.
While facing challenges in operational costs and market dynamics, Ionis Pharma remains well-positioned to leverage opportunities in genetic medicines and revenue diversification.

Ionis Pharma reports strong Q1 earnings and outlines growth plans

Ionis Pharma's Q1 performance solid with revenue growth and strong cash position
Company's strengths lie in FDA approvals, positive study data, and pipeline progress
Challenges include rising expenses, competitive landscape, and pricing strategies
Opportunities seen in PV market, HAE program, and growth prospects in coming years

Ionis Pharma reports strong Q2 performance and prepares for launches

Ionis Pharma's Q2 2023 earnings call highlighted strong performance, with revenue growth, key milestones in pipeline advancements, and a solid financial position.
The company faces challenges in study readout timing, competitive landscape changes, and market competition but has opportunities for growth through successful enrollment and product launches.
Key strengths include successful collaborations, encouraging interim results for SPINRAZA, and preparations for upcoming product launches, positioning Ionis Pharma for future success.
Overall, Ionis Pharma remains focused on advancing its pipeline, meeting financial guidance, and leveraging opportunities for growth in the biopharmaceutical market.

Ionis Pharma reports strong Q3 performance and neurology pipeline advancements

Ionis Pharma's Q3 earnings call highlighted strong performance, strategic successes, and advancements in the neurology pipeline.
The company faces challenges in a competitive landscape but has strengths in partnerships, innovation, and pricing strategies.
Opportunities lie in upcoming data releases, potential treatment benefits, and market differentiation strategies.
Overall, Ionis Pharma remains focused on delivering value to patients and investors through its innovative therapeutics.

Ionis Pharma reports robust 2023 results and eyes growth opportunities

Ionis Pharma's strong financial performance in 2023 and projected revenue for 2024 reflect a promising outlook for the company's growth and commercialization efforts.
While facing challenges in patient eligibility and treatment optimization, Ionis Pharma's focus on pipeline advancement and strategic investments positions it well for future success.
The company's emphasis on neurological disease platforms, upcoming data readouts, and collaborations present significant opportunities for expansion and innovation.

Ionis Pharma reports robust Q1 performance and advances key treatments

Ionis Pharma's Q1 2024 performance reflects strong revenue growth and progress in key pipeline programs, positioning the company for future success and sustained positive cash flow.
With a focus on strategic investments, innovative treatments, and upcoming data presentations, Ionis demonstrates a commitment to driving growth and addressing unmet medical needs.
While facing challenges in managing expenses and securing regulatory approvals, Ionis Pharma remains well-positioned to capitalize on market opportunities and partnerships for continued development and commercial success.

Ionis Pharma reports solid Q2 earnings, eyes growth through innovation

Ionis Pharma's Q2 performance reflects steady revenue growth and positive feedback on recent launches and ongoing trials.
The company's strengths lie in its innovative therapies, strong clinical profile, and strategic focus on expanding the product portfolio.
Challenges include sustaining momentum in competitive markets and ensuring successful commercialization of upcoming products.
Opportunities exist in market expansion, new patient segments, partnerships for pipeline growth, and investments in next-gen technologies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Ionis Pharmaceuticals, Inc. (IONS) Management Presents at BMO 2020 Prescriptions for Success Healthcare Conference Transcript

CARLSBAD, Calif., June 5, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following virtual investor conferences: William Blair 40th Annual Growth Stock Conference...

Ionis Pharmaceuticals to present at upcoming virtual investor conferences

Axsome Therapeutics

Vertex Pharmaceuticals

One big biotech and two small biotechs especially stand out as attractive picks.

Got $3,000? Here Are 3 Great Biotech Stocks to Buy Right Now

CARLSBAD, Calif., May 28, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2020 virtual Annual Meeting of Stockholders and provide a general corporate update on Thursday, June 4, 2020. This event will be webcast live on the...

Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders

Ionis Pharmaceuticals' (IONS) CEO Brett Monia on Q1 2020 Results - Earnings Call Transcript

Proofpoint

RingCentral

Shopify

A handful of companies seem immune to fallout from the COVID-19 pandemic. Some may even benefit from it.

4 Monster Stocks in the Making

Aphria

Huron Consulting Group

InterDigital

Tabula Rasa Healthcare

Invest in top-ranked stocks that are likely to beat their earnings estimates in the upcoming releases.

Grab 5 Top Stocks With Strong Earnings Beat Prospects

Ionis Pharmaceuticals (IONS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

Why Ionis Pharmaceuticals (IONS) Stock Might be a Great Pick

Grifols, S.A.

GRFS vs. IONS: Which Stock Is the Better Value Option?

GRFS or IONS: Which Is the Better Value Stock Right Now?

Ionis Pharmaceuticals' (IONS) CEO Brett Monia on Q4 2019 Results - Earnings Call Transcript

The biotechnology company's license fees increased almost 400% to $490 million.

Ionis Pharmaceuticals' Revenues Rose 85% in 2019

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 40.66% and 21.72%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharmaceuticals (IONS) Q4 Earnings and Revenues Surpass Estimates

The company is advancing a new treatment for people with Alexander disease.

Ionis Receives Orphan Drug Designation From EMA

Akcea Therapeutics

Both primary as well as multiple secondary endpoints were met in the trial.

Akcea and Ionis Confirm Positive Trial Results for Hypertriglyceridemia Treatment

Ionis, Akcea Confirmation With Hypertriglyceridemia Results

The drug will advance to studies in familial chylomicronemia syndrome and other diseases that result in high triglyceride levels.

Akcea and Ionis' Triglyceride-Lowering Drug Works in Mid-Stage Clinical Trial

Shares of Ionis Pharmaceuticals and Akcea Therapeutics popped Wednesday after the biotech companies said their high triglycerides treatment succeeded in a midstage study.
The post Will These Biotechs Rival A Top-Notch Stock In High Triglycerides?

Will These Biotechs Rival A Top-Notch Stock In High Triglycerides?

Akcea Therapeutics Inc. (NASDAQ: AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ: IONS) each made handy gains on Wednesday after they reported midstage results for their cardiovascular disease study.

Why This Cardiovascular Disease Study Could Be Huge

Investors are overly focused on one issue with this stock while the company is making progress on many fronts.

5 Reasons 2020 Will Be a Big Year for Ionis Pharmaceuticals

Biogen

Worms that were fed probiotics saw a reduction in proteins associated with the disease.

New Research Shows Probiotics Can Help Prevent Parkinson's

BOSTON and CARLSBAD, Calif., Jan.  10, 2020  (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the initiation of the CARDIO-TTRansform Phase 3 cardiovascular outcomes study for AKCEA-TTR-LRx in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR cardiomyopathy). 

Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy

Ionis: A Long-Term Buy On Earnings, Pipeline

BOSTON and CARLSBAD, Calif., Nov.  25, 2019  (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced initiation of the NEURO-TTRansform Phase 3 clinical trial for AKCEA-TTR-LRx in patients with polyneuropathy caused by h856ereditary TTR amyloidosis, or hATTR amyloidosis.

Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis

Ionis Pharmaceuticals (IONS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

News for Ionis Pharma Stock (IONS)